Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Marker Therapeutics (MRKR) over the last 9 years, with Q3 2025 value amounting to 173.3%.

  • Marker Therapeutics' EBITDA Margin fell 487000.0% to 173.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 876.6%, marking a year-over-year increase of 10403200.0%. This contributed to the annual value of 5559.19% for FY2024, which is 51188100.0% down from last year.
  • Per Marker Therapeutics' latest filing, its EBITDA Margin stood at 173.3% for Q3 2025, which was down 487000.0% from 494.79% recorded in Q2 2025.
  • In the past 5 years, Marker Therapeutics' EBITDA Margin registered a high of 93.29% during Q4 2024, and its lowest value of 1320.14% during Q1 2025.
  • In the last 4 years, Marker Therapeutics' EBITDA Margin had a median value of 400.28% in 2022 and averaged 482.66%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 11176200bps in 2024, then crashed by -11152500bps in 2025.
  • Over the past 4 years, Marker Therapeutics' EBITDA Margin (Quarter) stood at 400.28% in 2022, then soared by 31bps to 278.06% in 2023, then soared by 134bps to 93.29% in 2024, then crashed by -286bps to 173.3% in 2025.
  • Its EBITDA Margin was 173.3% in Q3 2025, compared to 494.79% in Q2 2025 and 1320.14% in Q1 2025.